Drug intelligence / Profile preview

GB-5313

Development stage
Preclinical
Lead developer
G2GBio
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Intraarticular
01

Overview

GB-5313 is an investigational sustained-release therapeutic candidate being developed by G2G Bio for the treatment of osteoarthritis. The drug utilizes G2G Bio's proprietary InnoLamp (Innovative Long-Acting MicroParticle) technology, which involves encapsulating an active pharmaceutical ingredient within biodegradable PLGA (poly lactic-co-glycolic acid) microspheres. This delivery system is designed to provide controlled, uniform drug release over extended periods—specifically targeting durations of one, three, or six months—following a single intra-articular injection. The goal of the program is to provide long-term pain management and improve patient convenience by reducing the frequency of clinical visits for joint injections. As of early 2024, the candidate is in the discovery and preclinical development stage.

Other names
GB-5313-G2G Bio-OsteoarthritisGB5313-G2G Bio-OsteoarthritisGB 5313-G2G Bio-Osteoarthritis

Beyond the preview

Go deeper on GB-5313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-5313.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call